Specifically, the downregulation of DYRK2's gene expression has been linked to increased stemness in breast cancer (102) and CML (72) via upregulation of transcription factor Krüppel-like factor 4. Here, DYRK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.